US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Xtrackers Nifty 500 India ETF

23.15

-0.0133-0.06%

Post-market: 23.12-0.0300-0.13%16:10 EDT

Volume:494

Turnover:11.43K

Market Cap:4.63M

PE:- -

High:23.15

Open:23.12

Low:23.12

Close:23.16

52wk High:27.40

52wk Low:20.52

Shares:200.00K

Float Shares:200.00K

Volume Ratio:0.63

T/O Rate:0.25%

Dividend:0.08

Dividend Rate:0.34%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Press Release: CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum

Immuron Reports FY26 Preliminary Results

Press Release: CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum

Gundara Enterprises Ceases to Be Substantial Holder in Industrial Minerals Ltd

Industrial Minerals Appoints New Director and Details Equity Interests

Industrial Minerals Issues New Shares and Confirms Compliance With Disclosure Rules

Industrial Minerals Ltd Issues 8.8 Million Unquoted Performance Rights

Industrial Minerals Seeks ASX Quotation for 45.8 Million New Shares

Industrial Minerals Completes Galleon Deal and Reshapes Board

Nxera to Book US$10m Milestone as FDA Clears Phase 2 Alzheimer’s Drug

Is HBM Holdings (SEHK:2142) Fully Valued After Its HBM7004 IND Approval?

Simply Wall St.

Caliway Gets FDA IND Nod for Phase 2 CBL-514 Trial of Abdominal Fat Reduction Drug; Shares Down 4%

MT Newswires Live

Press Release: InnoCare Reports 2026 Interim Results, Sustained Profitability and Key Milestones Achieved

Industrial Minerals Confirms Priority Gold Target at Laverton’s North Pool

Industrial Minerals Wins Strong Shareholder Backing for Galleon Metals Deal and Board Refresh

CSTONE PHARMA-B Gets NMPA Green Light for CS5007 Investigational New Drug Application

CStone Gains Rapid China IND Approval for EGFR/HER3 ADC CS5007

Protagenic Therapeutics Advances PT00114 Toward U.S. IND

Protagenic receives FDA pre-IND feedback supporting IND for PT00114

India's Central Bank Chief Says Its Net Short Dollar Position Is 'Very Manageable'

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/IND/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IND","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IND\",,,,,undefined,":{"symbol":"IND","market":"US","secType":"STK","nameCN":"Xtrackers Nifty 500 India ETF","latestPrice":23.145,"timestamp":1788206400000,"preClose":23.1583,"halted":0,"volume":494,"hourTrading":{"tag":"盘后","latestPrice":23.115,"preClose":23.145,"latestTime":"16:10 EDT","volume":7,"amount":162.015,"timestamp":1788207004404,"change":-0.03,"changeRate":-0.001296,"amplitude":0},"delay":0,"changeRate":-0.0005743081314259241,"floatShares":200001,"shares":200001,"eps":0,"marketStatus":"Closed","change":-0.0133,"latestTime":"08-31 16:00:00 EDT","open":23.115,"high":23.145,"low":23.115,"amount":11430,"amplitude":0.001295,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1788249600000},"marketStatusCode":5,"adr":0,"exchange":"NASDAQ","adjPreClose":23.1583,"sharesOutstanding":200001,"nav":23.107,"aum":4621406.79,"dividendRate":0.003409,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":23.115,"preClose":23.145,"latestTime":"16:10 EDT","volume":7,"amount":162.015,"timestamp":1788207004404,"change":-0.03,"changeRate":-0.001296,"amplitude":0},"volumeRatio":0.628339},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IND\",,,,,undefined,":{"symbol":"IND","floatShares":200001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.628339,"shares":200001,"dividePrice":0.0789,"high":23.145,"amplitude":0.001295,"preClose":23.1583,"low":23.115,"week52Low":20.515,"pbRate":"--","week52High":27.4,"institutionHeld":0,"latestPrice":23.145,"eps":0,"divideRate":0.003409,"volume":494,"delay":0,"ttmEps":0,"open":23.115,"prevYearClose":24.78,"prevWeekClose":23.1583,"prevMonthClose":22.885,"prevQuarterClose":22.88,"fiveDayClose":23.065,"twentyDayClose":23.01,"sixtyDayClose":22.2234},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IND\",params:#limit:5,,,undefined,":[{"date":"2026-06-18","symbol":"IND","amount":0.07775,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-18","defaultRemindTime":1781789400000,"name":"Xtrackers Nifty 500 India ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-26","payableDate":"2026-06-18","currency":"USD","dateTimestamp":1781755200000,"payDate":"2026-06-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IND\",market:\"US\",,,undefined,":[{"executeDate":"2026-06-18","recordDate":"2026-06-18","paymentDate":"2026-06-26","value":0.07775,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IND\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IND\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2663600336","title":"Press Release: CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=2663600336","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663600336?lang=en_us&edition=fundamental","pubTime":"2026-08-31 20:23","pubTimestamp":1788178980,"startTime":"0","endTime":"0","summary":"CS2009 Achieved Key Clinical Validations for Efficacy and SafetyAs of August 2026, updated data further confirmed the favorable safety profile of CS2009 and demonstrated strengthened efficacy across multiple key cohorts compared with the data presented at ASCO in May 2026. With expanded patient enrollment and longer follow-up, improvements were observed in both the objective response rate  and duration of response :Compelling monotherapy efficacy in first-line non-small cell lung cancer -- At the 30 mg/kg dose level, CS2009 achieved an ORR of 100% and a disease. control rate  of 100% in patients with PD-L1 TPS >=50%. In the. broader PD--L1 TPS >=1% population, the ORR was 70.8% and DCR was 91.7%.Monotherapy efficacy in Immunotherapy -pretreated NSCLC and IO-nonresponsive \"cold tumors\" further validates CTLA-4 activity and efficacy.-- In second-line NSCLC patients (all previously treated with IO plus. -- In patients with heavily pretreated metastatic colorectal cancer ,CS2009 monotherap","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0210528500.USD","IE00BFXG0V08.USD","BK1161","LU1223082519.USD","IE00B5TLWC47.USD","IND","BK1574","BK4211","LU2211817866.USD","LU1093756168.USD","CDE","BK4533","BK4585","LU2413666426.HKD","LU1223082196.USD","BK4567","BK4548","LU2487616109.SGD","MTD","LU0053666078.USD","XME","SIL","LU1223083913.SGD","BK4017","SGDM","BK4107","PFS","LU0347712357.USD","BK4588","ORR","LU1093756325.SGD","IE00BYQQ9H92.USD","02616","LU1721428933.USD","L","BK4121","LU2413666699.HKD","GDXJ","BK4195"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662061937","title":"Immuron Reports FY26 Preliminary Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2662061937","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662061937?lang=en_us&edition=fundamental","pubTime":"2026-08-28 18:00","pubTimestamp":1787911200,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia, Aug.  28, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to release its preliminary results for financial year ending 30 June 2026. Results exceed e","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/28/3352589/37134/en/immuron-reports-fy26-preliminary-results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMRN","BK4566","BK4585","BK4139","TD","GSIB","IND","BK4207"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662955085","title":"Press Release: CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=2662955085","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662955085?lang=en_us&edition=fundamental","pubTime":"2026-08-27 22:15","pubTimestamp":1787840100,"startTime":"0","endTime":"0","summary":"CS2009 Achieved Key Clinical Validations for Efficacy and SafetyAs of August 2026, updated data further confirmed the favorable safety profile of CS2009 and demonstrated strengthened efficacy across multiple key cohorts compared with the data presented at ASCO in May 2026. With expanded patient enrollment and longer follow-up, improvements were observed in both the objective response rate  and duration of response :Compelling monotherapy efficacy in first-line non-small cell lung cancer -- At the 30 mg/kg dose level, CS2009 achieved an ORR of 100% and a disease. control rate  of 100% in patients with PD-L1 TPS >=50%. In the. broader PD--L1 TPS >=1% population, the ORR was 70.8% and DCR was 91.7%.Monotherapy efficacy in Immunotherapy -pretreated NSCLC and IO-nonresponsive \"cold tumors\" further validates CTLA-4 activity and efficacy-- In second-line NSCLC patients (all previously treated with IO plus. -- In patients with heavily pretreated metastatic colorectal cancer ,CS2009 monotherapy","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GDXJ","LU1093756168.USD","BK4533","CDE","LU1721428933.USD","BK4567","LU0053666078.USD","BK4121","BK4107","02616","PFS","LU0210528500.USD","MTD","LU0347712357.USD","BK4585","LU1223082519.USD","IND","BK4017","SIL","XME","L","LU1093756325.SGD","LU2487616109.SGD","SGDM","LU2413666426.HKD","LU2211817866.USD","IE00B5TLWC47.USD","IE00BFXG0V08.USD","ORR","BK1574","BK4548","BK4588","BK1161","LU2413666699.HKD","BK4211","IE00BYQQ9H92.USD","BK4195","LU1223083913.SGD","LU1223082196.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662775571","title":"Gundara Enterprises Ceases to Be Substantial Holder in Industrial Minerals Ltd","url":"https://stock-news.laohu8.com/highlight/detail?id=2662775571","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662775571?lang=en_us&edition=fundamental","pubTime":"2026-08-27 14:21","pubTimestamp":1787811702,"startTime":"0","endTime":"0","summary":"Industrial Minerals Limited ( ($AU:IND) ) has issued an announcement. Industrial Minerals Ltd has disclosed that Gundara Enterprises Pty Ltd has ce...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gundara-enterprises-ceases-to-be-substantial-holder-in-industrial-minerals-ltd?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gundara-enterprises-ceases-to-be-substantial-holder-in-industrial-minerals-ltd?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MTX","IND","BK4109"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662773179","title":"Industrial Minerals Appoints New Director and Details Equity Interests","url":"https://stock-news.laohu8.com/highlight/detail?id=2662773179","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662773179?lang=en_us&edition=fundamental","pubTime":"2026-08-27 14:15","pubTimestamp":1787811341,"startTime":"0","endTime":"0","summary":"An announcement from Industrial Minerals Limited ( ($AU:IND) ) is now available. Industrial Minerals Limited has appointed Warrick Clent as a direc...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/industrial-minerals-appoints-new-director-and-details-equity-interests?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/industrial-minerals-appoints-new-director-and-details-equity-interests?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MTX","BK4215","BK4585","BK4109","REZ","EQR","BK4588","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662778067","title":"Industrial Minerals Issues New Shares and Confirms Compliance With Disclosure Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2662778067","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662778067?lang=en_us&edition=fundamental","pubTime":"2026-08-27 13:57","pubTimestamp":1787810260,"startTime":"0","endTime":"0","summary":"Industrial Minerals Limited ( ($AU:IND) ) has issued an announcement. Industrial Minerals Ltd has issued 62,367,716 fully paid ordinary shares foll...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/industrial-minerals-issues-new-shares-and-confirms-compliance-with-disclosure-rules?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/industrial-minerals-issues-new-shares-and-confirms-compliance-with-disclosure-rules?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IND","MTX","BK4109"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662778085","title":"Industrial Minerals Ltd Issues 8.8 Million Unquoted Performance Rights","url":"https://stock-news.laohu8.com/highlight/detail?id=2662778085","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662778085?lang=en_us&edition=fundamental","pubTime":"2026-08-27 13:57","pubTimestamp":1787810243,"startTime":"0","endTime":"0","summary":"An update from Industrial Minerals Limited ( ($AU:IND) ) is now available. Industrial Minerals Ltd has notified the market of the issuance of a ser...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/industrial-minerals-ltd-issues-8-8-million-unquoted-performance-rights?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/industrial-minerals-ltd-issues-8-8-million-unquoted-performance-rights?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IND","MTX","BK4109"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662780307","title":"Industrial Minerals Seeks ASX Quotation for 45.8 Million New Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2662780307","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662780307?lang=en_us&edition=fundamental","pubTime":"2026-08-27 13:50","pubTimestamp":1787809808,"startTime":"0","endTime":"0","summary":"Industrial Minerals Limited ( ($AU:IND) ) has provided an announcement. Industrial Minerals Ltd has lodged an application with the ASX for the quot...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/industrial-minerals-seeks-asx-quotation-for-45-8-million-new-shares?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/industrial-minerals-seeks-asx-quotation-for-45-8-million-new-shares?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IND","MTX","BK4109"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662780987","title":"Industrial Minerals Completes Galleon Deal and Reshapes Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2662780987","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662780987?lang=en_us&edition=fundamental","pubTime":"2026-08-27 13:49","pubTimestamp":1787809799,"startTime":"0","endTime":"0","summary":"Industrial Minerals Limited ( ($AU:IND) ) has provided an announcement. Industrial Minerals Ltd, an Australian exploration company, is building a p...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/industrial-minerals-completes-galleon-deal-and-reshapes-board?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/industrial-minerals-completes-galleon-deal-and-reshapes-board?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IND","BK4109","MTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662795913","title":"Nxera to Book US$10m Milestone as FDA Clears Phase 2 Alzheimer’s Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2662795913","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662795913?lang=en_us&edition=fundamental","pubTime":"2026-08-26 15:52","pubTimestamp":1787730745,"startTime":"0","endTime":"0","summary":"Sosei Group ( ($JP:4565) ) has provided an update. Nxera Pharma’s partner Neurocrine Biosciences has secured FDA IND acceptance for a Phase 2 trial...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nxera-to-book-us10m-milestone-as-fda-clears-phase-2-alzheimers-drug?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nxera-to-book-us10m-milestone-as-fda-clears-phase-2-alzheimers-drug?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","IND","BBC","PSIL","LABU","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662349759","title":"Is HBM Holdings (SEHK:2142) Fully Valued After Its HBM7004 IND Approval?","url":"https://stock-news.laohu8.com/highlight/detail?id=2662349759","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662349759?lang=en_us&edition=fundamental","pubTime":"2026-08-26 00:18","pubTimestamp":1787674691,"startTime":"0","endTime":"0","summary":"HBM Holdings (SEHK:2142) is back in focus after Harbour BioMed received approval from China’s National Medical Products Administration for an Investigational New Drug application linked to HBM7004, a bispecific antibody targeting advanced solid tumors.\nSee our latest analysis for HBM Holdings.\nThe HBM7004 IND approval arrives as HBM Holdings trades at HK$16.54, with a 30-day share price return of 32.21% and a 90-day share price return of 40.77%, while the 3-year total shareholder return is...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2142/hbm-holdings-shares/news/is-hbm-holdings-sehk2142-fully-valued-after-its-hbm7004-ind","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2142/hbm-holdings-shares/news/is-hbm-holdings-sehk2142-fully-valued-after-its-hbm7004-ind","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["HBMX","BK4168","HBM","BK4588","DRAM","DRMY","MULL","RAMZ","MUYY","DRMP","02142","DISK","MUG","MUD","RAM","COPP","DRAL","MUZ","MUU","MIC","BK1574","DCF","BK1583","BK1161","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662778308","title":"Caliway Gets FDA IND Nod for Phase 2 CBL-514 Trial of Abdominal Fat Reduction Drug; Shares Down 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662778308","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662778308?lang=en_us&edition=fundamental","pubTime":"2026-08-25 12:19","pubTimestamp":1787631588,"startTime":"0","endTime":"0","summary":"Caliway Biopharmaceuticals Co Ltd  has received approval from the U.S. Food and Drug Administration for an investigational new drug application for a second-phase trial of the combination use of CBL-514 and Zepbound to reduce abdominal subcutaneous fat in overweight or obese adults.The company plans to enroll 120 subjects in the US for Phase 2 of the trial to evaluate the efficacy, safety, and tolerability of the combination use of CBL-514 and tirzepatide, according to a Monday filing to the Taiwan stock exchange.The company's shares were down nearly 4% in Tuesday's trade.This study will evaluate abdominal fat volume change measured by MRI as an efficacy endpoint.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LABU","BK4588","BK4585","BK4080","IND","CBL","BK4231"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661695272","title":"Press Release: InnoCare Reports 2026 Interim Results, Sustained Profitability and Key Milestones Achieved","url":"https://stock-news.laohu8.com/highlight/detail?id=2661695272","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661695272?lang=en_us&edition=fundamental","pubTime":"2026-08-24 22:32","pubTimestamp":1787581920,"startTime":"0","endTime":"0","summary":"BEIJING, Aug. 24, 2026  -- InnoCare Pharma , a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the interim results and business highlights for the six months ended 30 June 2026.InnoCare delivered robust revenue growth and strengthened profitability in the first half of 2026, driven by strong commercial execution and global business development collaborations. In the first half of 2026, the Company's revenue grew by 55.5% year-on-year to RMB 1.1 billion, and profit reached RMB 239.7 million, a turnaround from a loss in the same period last year. These results reflect the successful implementation of the Company's strategy driven by innovation, commercialization and globalization.In the first half of 2026, InnoCare continued to accelerate innovation, achieving a series of key milestones.-- 1 NDA approval: Orelabrutinib was approved in Australia.-- 2 NDA acceptances: The NDA applications for orelabrutinib in primary. immune thrombocytopenia  a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PFS","BK4567","CR","BK4077","BK4588","LU2413666699.HKD","IE00B5TLWC47.USD","LU2413666426.HKD","LU2211817866.USD","ITP","IE00BFXG0V08.USD","SLE","BK4548","IE00BYQQ9H92.USD","IND","LU1093756325.SGD","LU1093756168.USD","BK1574","09969","LU0347712357.USD","ORR","BK4161","BK4533","MTD","BK4195","BK4211","BK1161","BK4121","BK4585","LU1721428933.USD","BK4199"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661048246","title":"Industrial Minerals Confirms Priority Gold Target at Laverton’s North Pool","url":"https://stock-news.laohu8.com/highlight/detail?id=2661048246","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661048246?lang=en_us&edition=fundamental","pubTime":"2026-08-24 06:39","pubTimestamp":1787524775,"startTime":"0","endTime":"0","summary":"Industrial Minerals Limited ( ($AU:IND) ) has issued an update. Industrial Minerals has reinterpreted existing aeromagnetic and gravity data over t...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/industrial-minerals-confirms-priority-gold-target-at-lavertons-north-pool?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/industrial-minerals-confirms-priority-gold-target-at-lavertons-north-pool?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4159","BK4109","IE00B64QTZ34.USD","POOL","BK4585","BK4567","MTX","BK4588","IND","BK4559"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661251858","title":"Industrial Minerals Wins Strong Shareholder Backing for Galleon Metals Deal and Board Refresh","url":"https://stock-news.laohu8.com/highlight/detail?id=2661251858","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661251858?lang=en_us&edition=fundamental","pubTime":"2026-08-21 11:17","pubTimestamp":1787282249,"startTime":"0","endTime":"0","summary":"Industrial Minerals Limited ( ($AU:IND) ) has shared an announcement. Industrial Minerals Limited shareholders have overwhelmingly approved all res...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/industrial-minerals-wins-strong-shareholder-backing-for-galleon-metals-deal-and-board-refresh?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/industrial-minerals-wins-strong-shareholder-backing-for-galleon-metals-deal-and-board-refresh?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MTX","BK4109","IND","BK4535","PICK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163462206","title":"CSTONE PHARMA-B Gets NMPA Green Light for CS5007 Investigational New Drug Application","url":"https://stock-news.laohu8.com/highlight/detail?id=1163462206","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163462206?lang=en_us&edition=fundamental","pubTime":"2026-08-21 06:12","pubTimestamp":1787263936,"startTime":"0","endTime":"0","summary":"CSTONE PHARMA-B (02616) has announced that the Investigational New Drug (IND) application for CS5007, an EGFR/HER3 bispecific antibody-drug conjugate (ADC) and one of the core candidates in the...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4231","BK4080","NETL","BK1161","IND","BK1574","02616","ADC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661302932","title":"CStone Gains Rapid China IND Approval for EGFR/HER3 ADC CS5007","url":"https://stock-news.laohu8.com/highlight/detail?id=2661302932","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661302932?lang=en_us&edition=fundamental","pubTime":"2026-08-21 06:07","pubTimestamp":1787263635,"startTime":"0","endTime":"0","summary":"CStone Pharmaceuticals ( ($HK:2616) ) just unveiled an announcement. CStone Pharmaceuticals has secured rapid investigational new drug approval in ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cstone-gains-rapid-china-ind-approval-for-egfr-her3-adc-cs5007?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cstone-gains-rapid-china-ind-approval-for-egfr-her3-adc-cs5007?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL","BK4231","TBXU","IND","ADC","NETL","BK4080"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661235479","title":"Protagenic Therapeutics Advances PT00114 Toward U.S. IND","url":"https://stock-news.laohu8.com/highlight/detail?id=2661235479","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661235479?lang=en_us&edition=fundamental","pubTime":"2026-08-21 00:04","pubTimestamp":1787241844,"startTime":"0","endTime":"0","summary":"Protagenic Therapeutics ( ($PTIX) ) has issued an announcement. On August 20, 2026, Protagenic Therapeutics announced that the U.S. Food and Drug A...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/protagenic-therapeutics-advances-pt00114-toward-u-s-ind?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/protagenic-therapeutics-advances-pt00114-toward-u-s-ind?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","LENZ","IND","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660735282","title":"Protagenic receives FDA pre-IND feedback supporting IND for PT00114","url":"https://stock-news.laohu8.com/highlight/detail?id=2660735282","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660735282?lang=en_us&edition=fundamental","pubTime":"2026-08-20 20:50","pubTimestamp":1787230244,"startTime":"0","endTime":"0","summary":"Protagenic Therapeutics (PTIX) announced that it has received written responses from the U.S. Food and Drug Administration, FDA, to its Type B pre-...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/protagenic-receives-fda-pre-ind-feedback-supporting-ind-for-pt00114-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/protagenic-receives-fda-pre-ind-feedback-supporting-ind-for-pt00114-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","PTIX","BK4139","BK4588","IND","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122741128","title":"India's Central Bank Chief Says Its Net Short Dollar Position Is 'Very Manageable'","url":"https://stock-news.laohu8.com/highlight/detail?id=1122741128","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122741128?lang=en_us&edition=fundamental","pubTime":"2026-08-20 10:40","pubTimestamp":1787193618,"startTime":"0","endTime":"0","summary":"Reserve Bank of India Governor Sanjay Malhotra stated that the central bank's net forward short dollar position remains at a \"very manageable\" level, citing prior liquidity swap arrangements and...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","UUP","SMIN","FLIN","INDA","INDE","UDN","FLIBF","INDL","IND","INCO","INQQ","IMVP","PIN","EPI","BK4585","IOPP","NFTY","TAJX","BK4523","GIND","INDY","SCIN","NDIA"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}]}}